- Home
- ENTX vs SACH Comparison
ENTX vs SACH Comparison
Compare ENTX & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- SACH
- Stock Information
- Founded
- ENTX 2010
- SACH 2010
- Country
- ENTX Israel
- SACH United States
- Employees
- ENTX N/A
- SACH N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- SACH Real Estate Investment Trusts
- Sector
- ENTX Health Care
- SACH Real Estate
- Exchange
- ENTX Nasdaq
- SACH Nasdaq
- Market Cap
- ENTX 67.2M
- SACH 61.5M
- IPO Year
- ENTX 2018
- SACH 2017
- Fundamental
- Price
- ENTX $2.25
- SACH $1.19
- Analyst Decision
- ENTX Strong Buy
- SACH Buy
- Analyst Count
- ENTX 1
- SACH 2
- Target Price
- ENTX $10.00
- SACH $2.25
- AVG Volume (30 Days)
- ENTX 54.3K
- SACH 536.0K
- Earning Date
- ENTX 11-08-2024
- SACH 11-14-2024
- Dividend Yield
- ENTX N/A
- SACH 19.59%
- EPS Growth
- ENTX N/A
- SACH N/A
- EPS
- ENTX N/A
- SACH N/A
- Revenue
- ENTX $99,000.00
- SACH $10,951,064.00
- Revenue This Year
- ENTX N/A
- SACH N/A
- Revenue Next Year
- ENTX N/A
- SACH N/A
- P/E Ratio
- ENTX N/A
- SACH N/A
- Revenue Growth
- ENTX 607.14
- SACH N/A
- 52 Week Low
- ENTX $0.52
- SACH $1.21
- 52 Week High
- ENTX $3.35
- SACH $4.64
- Technical
- Relative Strength Index (RSI)
- ENTX 68.35
- SACH 21.59
- Support Level
- ENTX $2.02
- SACH $1.35
- Resistance Level
- ENTX $2.28
- SACH $1.48
- Average True Range (ATR)
- ENTX 0.17
- SACH 0.08
- MACD
- ENTX 0.04
- SACH 0.01
- Stochastic Oscillator
- ENTX 77.01
- SACH 1.28
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.